Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China-Reference-Cited by-同舟云学术

Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China

Published:2018-09 Issue:9 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Xie Yong¹,Zhu Zhenhua¹,Wang Jiangbin²,Zhang Lingxia³,Zhang Zhenyu⁴,Lu Hong⁵,Zeng Zhirong⁶,Chen Shiyao⁷,Liu Dongsheng¹,Lv Nonghua¹

Affiliation:

1. The First Affiliated Hospital of Nanchang University, Nanchang, China

2. China-Japan Union Hospital, Jilin University, Changchun, China

3. Central Hospital of Xi'an City, Xi'an, China

4. Nanjing No. 1 Hospital, Nanjing, China

5. Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

6. The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

7. Zhongshan Hospital, Fudan University, Shanghai, China

Abstract

The objective of this study was to investigate the efficacy and safety of 10-day bismuth quadruple therapy with amoxicillin, tetracycline, or clarithromycin and different doses of rabeprazole for first-line treatment of Helicobacter pylori infection. This multicenter, randomized, parallel-controlled clinical trial was conducted between March 2013 and August 2014.

Funder

National Key Research and Development Program of China

National Science and Technology Major Projects for “Major New Drugs Innovation and Development” of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00432-18

Reference25 articles.

1. Helicobacter pylori Public Health Implications

2. Antimicrobial Resistance Incidence and Risk Factors amongHelicobacter pylori–Infected Persons, United States